$OFIX

Fisher Patrick sold $1K of OFIX

Fisher Patrick (President, Global Limb Recon) sold 150 shares of Orthofix Medical Inc. (OFIX) at $9.39 on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fisher Patrick
Published Sep 3, 2026, 8:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 11:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OFIX
Neutral
high confidence
Mentioned
$OFIX
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OFIXNeutralLow
01

Why it matters

The disclosed sale is routine and unlikely to move the stock, but it provides transparency for investors.

02

Market read

Minor insider sale with negligible market impact; primarily of interest to compliance‑focused investors.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 2/10Novelty 4/10Timing: post‑market Sep 1, 2026 filing Sep 3

Background

Form 4 filings disclose insider transactions; a 10b5-1 plan indicates pre‑arranged sales.

Company-level read

Ticker impact

$OFIXNeutralHigh confidence
Context

President Fisher Patrick sold 150 shares for $1,408.50 via a 10b5-1 plan, filing a Form 4 on Sep 3, 2026.

Expected impact

Likely negligible effect on OFIX price.

Evidence & confidence

The transaction represents less than 0.01% of total shares outstanding and is disclosed as a routine 10b5-1 sale.

Market effects

No broader sector impact; Orthofix operates in medical devices niche.

Limited to US small‑cap investors.

Minimal global relevance.

Counterpoint

Even small insider sales can signal confidence concerns; monitor for further disposals.

Key entities

  • Fisher Patrick

    President, Global Limb Recon at Orthofix Medical.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OFIXMed

Orthofix Medical Inc. Q2 2026 Earnings Call Summary

Orthofix Medical Inc. reported Q2 2026 earnings call updates, emphasizing a shift toward distributor quality and asset utilization. Management expects 2026 net sales and EBITDA guidance to rise by $7 million, citing $12 million Medicare reimbursement restoration and $15 million European distributor benefit, partly offset by weaker smaller spine distributors. Medicare bone stimulator reimbursement was restored retroactive to May 18, 2026.

$OFIXMed

These 7 Small Caps Are On Fire In July: Here's Why - ExxonMobil Holdings (NYSE:XOM), Vertex Pharmaceutica

The Russell 2000 stayed near 3,000 with little movement, while seven small-cap stocks gained at least 28% in four sessions. The article cites July surges for Orthofix (OFIX) on CMS reimbursement reversal, REGENXBIO (RGNX) on FDA resubmission alignment and AbbVie milestone, Verastem (VSTM) on short-squeeze setup, ADC Therapeutics (ADCT) rebound, Sable Offshore (SOC) refinancing, Rapid7 (RPD) takeover speculation, and Crinetics (CRNX) surge toward an offer price.

$LUCYMedAI 8/10

Top Biotech Gainers: LUCY Shines, SEER Gets Takeover Offer, OFIX, ENOV Rally On CMS Update

Biotech gainers: Innovative Eyewear (LUCY) rose 63% after preliminary Q2 2026 net sales of ~$0.99M (+71% YoY) and new retail orders; Seer (SEER) jumped 35% on an unsolicited $2.45/share cash takeover proposal plus contingent value rights; Orthofix (OFIX) and Enovis (ENOV) gained 16%/15% after CMS withdrew reimbursement changes for non-invasive bone growth stimulators.

$OFIXMedAI 8/10

Why is Orthofix Medical stock surging today? By Investing.com

Orthofix Medical shares rose 15.3% after the company said CMS reversed earlier Medicare billing/fee-schedule changes for non-invasive bone growth stimulators, restoring reimbursement to prior levels. CMS issued revised guidance July 1, 2026, withdrawing modifications tied to HCPCS codes. The stock moved from near $8.85 toward $11.46; insiders sold about $2.7M over three months.